{"id":8250,"date":"2019-11-07T13:51:48","date_gmt":"2019-11-07T13:51:48","guid":{"rendered":"https:\/\/www.dlongwood.com\/fusionplex-pan-solid-tumor-v2-3\/"},"modified":"2025-05-15T07:58:50","modified_gmt":"2025-05-15T07:58:50","slug":"fusionplex-pan-solid-tumor-v2","status":"publish","type":"productos","link":"https:\/\/www.dlongwood.com\/en\/product-catalog\/fusionplex-pan-solid-tumor-v2\/","title":{"rendered":"FusionPlex\u00ae Pan Solid Tumor v2"},"content":{"rendered":"\n

The FusionPlex\u00ae Pan Solid Tumor v2 panel is a targeted next-generation sequencing <\/strong>(NGS) research product that expands on the FusionPlex Solid Tumor panel to include key fusions and variants<\/strong> relevant across solid tumors and sarcomas in 137 genes<\/strong>.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n
<\/div>\n\n\n\n

Representing our most comprehensive fusion coverage, the updated design includes key fusions and variants.<\/p>\n\n\n\n

FusionPlex\u00ae uses RNA<\/strong> instead of DNA as input material, which allows for more accurate and more cost-effective fusion detection<\/strong> than DNA-based hybrid capture techniques. FusionPlex\u00ae places gene-specific primers near known fusion breakpoints to identify RNA abnormalities with a single primer. Because FusionPlex\u00ae can identify known and novel alterations <\/strong>with a limited number of primers, it can detect fusions more efficiently and accurately than DNA-based approaches.<\/p>\n\n\n\n

This panel uses Anchored Multiplex PCR (AMP\u2122)<\/strong>-based enrichment to detect all fusions associated with the genes in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.<\/p>\n\n\n\n

Archer Analysis <\/strong>software allows the analysis and interpretation of the data.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Comprehensive Fusion Detection<\/strong><\/p>\n\n\n\n

AMP\u2122 chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.<\/p>\n\n\n\n

Splice Variant<\/strong><\/p>\n\n\n\n

Detect cancer-associated isoforms and alternative splicing events.<\/p>\n\n\n\n

Low Input<\/strong><\/p>\n\n\n\n

Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.<\/p>\n\n\n\n

Customization<\/strong><\/p>\n\n\n\n

Possibility to create from scratch or modify any panel.<\/p>\n\n\n\n

<\/div>\n\n\n\n
Gene Targets<\/strong><\/td>137<\/td><\/tr>
Input Nucleic Acid Required*<\/strong><\/td>\u226510 ng<\/td><\/tr>
Unique Molecular On-Target %<\/strong><\/td>>96%<\/td><\/tr>
Hands-On Time<\/strong><\/td>3.5 hours<\/td><\/tr>
Total Time<\/strong><\/td>1.5 days<\/td><\/tr>
Platform<\/strong><\/td>Illumina\u00ae e Ion Torrent\u2122<\/td><\/tr>
Sample Types<\/strong><\/td>Fresh, frozen and FFPE<\/td><\/tr><\/tbody><\/table>
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200ng is recommended.<\/figcaption><\/figure>\n\n\n\n